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Abstract: A series of cyclometallated mono- and di-nuclear 
platinum(II) complexes and the parent organic ligand, 2,6-
diphenylpyridine 1 (HC^N^CH), have been synthesized and 
characterized. This library of compounds includes [(C^N^C)Pt(II)(L)] 
(L = dimethylsulfoxide (DMSO) 2 and triphenylphosphine (PPh3) 3) 
and [((C^N^C)Pt(II))2(L`)] (where L` = N-heterocycles (pyrazine (pyr) 
4, 4,4`-bipyridine (4,4`-bipy) 5 or diphosphine (1,4-
bis(diphenylphosphino)butane (dppb) 6). Their cytotoxicity was 
assessed against four cancerous cell lines and one normal cell line, 
with results highlighting significantly increased antiproliferative activity 
for the dinuclear complexes (4-6), when compared to the 
mononucleated species (2 and 3). Complex 6 is the most promising 
candidate, displaying very high selectivity towards cancerous cells, 
with selectivity index (SI) values > 29.5 (A2780) and > 11.2 
(A2780cisR), and outperforming cisplatin by > 4-fold and > 18-fold 
respectively. 
Introduction 
Since the approval of the chemotherapeutic drug cisplatin, by the 
FDA in 1978, platinum(II)-based complexes have become integral 
in the clinical treatment of a range of different cancers.1 However, 
clinical platinum(II) anticancer drugs have several drawbacks 
associated with their use, including intrinsic and acquired 
resistance, lack of selectivity and neurotoxic side effects.2 
Consequently, this has generated great interest in the 
development of alternative platinum(II) complexes which have the 
potential to address the significant disadvantages linked to 
current clinical platinum complexes.3,4  
Cyclometallated platinum(II) complexes have emerged as 
attractive alternatives to existing clinical antiproliferative platinum 
drugs, and several compounds were reported to possess 
moderate to potent cytotoxicity against cancer cell lines that are 
resistant to current platinum(II) anticancer drugs.5,6 To date, 
cyclometallated platinum(II) compounds bearing a diverse range 
of tridentate organic π-ligands scaffolds including, C^N^S,8 
C^N^N,9 N^C^N10 and N^N^N11 have been reported to display up 
to sub-micromolar potency against a range of human cell lines 
e.g. breast adenocarcinoma (MCF-7) and colon carcinoma 
(HCT116).5  
Early reports from Lowe and co-workers outlined the potent 
cytotoxicity of cyclometallated platinum(II)-complexes 
incorporating a N^N^N terpyridine (terpy) ligand scaffold, and a 
range of N-heterocycles and thiolates in the fourth coordination 
site, against a panel of human cancer cell lines including two 
human ovarian carcinomas, A2780 and A2780cisR.12 Following 
on from this initial work, several groups have demonstrated the 
significant antiproliferative properties of platinum(II)-terpy 
systems, with reports of the biological activity rivalling that of 
cisplatin in a diverse array of human cancer cell lines.13-18 
However, the cytotoxicity of cyclometallated, C^N^C platinum(II) 
compounds has not been widely studied.19,20  Klein and co-
workers showed that a series of cyclometallated complexes 
based on [(C^N^C)Pt(II)(L)], wherein C^N^C is a tridentate 
dianionic cyclometalating motif bearing a range of aryl groups; 
including phenyl, naphthyl and dibenzoacridine derivatives and L 
= DMSO or acetonitrile (MeCN), displayed good to moderate 
cytotoxicity against colorectal adenocarcinoma (HT-29) and 
breast adenocarcinoma (MDA-MB-231) cell lines.21 
Polynuclear platinum(II) complexes represent an important 
growing class of anticancer agents with potential clinical 
significance.22-25 Developing an understanding of the structure-
activity relationships (SARs) within classes of biologically active 
complexes is integral for optimization of their performance.12,26-29 
Che and co-workers probed the importance of nuclearity on the 
SAR of a series of cyclometallated, tridentate C^N^N platinum(II) 
complexes, establishing that dinuclear species display more than 
one order of magnitude higher cytotoxicity than their monomeric 
analogues against five human carcinoma cell lines.15,30 Che and 
co-workers also established the significance of linker size on the 
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antiproliferative activity of a related series of [((C^N^N)Pt)2(μ-
NHC)]+ platinum(II) complexes where HC^N^N = 6-phenyl-2,2`-
bipyridyl and μ-NHC = a bridging N-heterocyclic carbene ligand. 
They showed that through increasing the length of the linker 
between the two metal centers, up to a 2-fold increase in 
cytotoxicity was induced against a panel of human cell lines, 
including cervix epithelioid carcinoma (HeLa), heptacellular 
carcinoma (HepG2) and nasopharyngeal carcinoma (SUNE1).24 
In the same study, Che and co-workers identified that analogous 
mononuclear complexes, [(C^N^N)Pt(NHC)]+ displayed 
significantly higher antiproliferative activity, with nanomolar to 
sub-micromolar potency (IC50 = 0.057 - 1.3 M), compared to the 
dinuclear [((C^N^N)Pt)2(μ-NHC)]+ platinum(II) complexes, (IC50 = 
3.9 – 9.4 M) against three tested cancer cell lines (HeLa, HepG2 
and SUNE1).24 Lowe and co-workers investigated the influence of 
linker rigidity on the cytotoxicity of a series of binuclear 
[((N^N^N)Pt)2(bipy)] (where N^N^N = terpy and bipy is a range of 
pyridine substituted derivatives connected by different linker 
groups) against several human ovarian cell lines including those 
resistant to cisplatin and doxorubicin; CH1, CH1cis, CH1dox, 
A2780 and A2780cisR. Generally, they found that the presence 
of short rigid linkers, e.g. 4,4`-bipyridine (4,4`-bipy), between the 
metal centers generated complexes with potent cytotoxicity 
against the tested cancer cell lines including nanomolar IC50 
values against the doxorubicin resistant ovarian cell line 
CH1dox.12a It is evident from the studies by Che and Lowe that 
the cytotoxicity of dinuclear cyclometallated platinum(II) 
complexes is highly dependent on several factors, including the 
backbone of the structure and the nature of the linker ligand. 
However, despite the increasing importance of cyclometallated 
platinum(II)-based complexes as potential anticancer 
therapeutics, reports on systematic studies to elucidate SARs for 
this class of compounds are limited.  
In this study, we investigate the SARs for a series of mono- and 
di-nuclear cyclometallated C^N^C platinum(II) compounds 
(Figure 1), [(C^N^C)Pt(II)(L)] and [((C^N^C)Pt(II))2(L`)] 
respectively, (where HC^N^CH = diphenylpyridine), against a 
range of cancer cell lines. This series of cyclometallated 
platinum(II) complexes were designed to consider the influence of 
three important structural features; 1) changes to the nature of the  
 
 
Figure 1. Library of compounds employed in this study. Ligand 1, 
mononuclear complexes 2 and 3 and dinuclear complexes 4-6. 
 
donor atom at the fourth coordination site of the metal center (i.e. 
L and L`) (from sulfoxide, phosphines and N-heterocycles), 2) 
size of ligand spacer between the two metal centers for two 
dinuclear complexes (from pyrazine (pyr) to 4,4`-bipy) and 3) 
nuclearity of the complex (from mono- and di-nuclear). We also 
report chemosensitivity studies against a normal cell type, 
showing that the most promising candidate, [((C^N^C)Pt(II))2(L`)] 
(L` = 1,4-bis(diphenylphosphino)butane (dppb)), is non-toxic 
towards normal cells, unlike cisplatin, which demonstrates high 
cytotoxicity.  
Results and Discussion 
Design and Synthesis of Library of Compounds 
The library of compounds consists of a ligand, 2,6-
diphenylpyridine 1 (HC^N^CH), two mononuclear complexes, 
[(C^N^C)Pt(DMSO)] 2 (where DMSO = dimethylsulfoxide) and 
[(C^N^C)Pt(PPh3)] 3 (where PPh3 = triphenylphosphine), and 
three dinuclear platinum(II) complexes [((C^N^C)Pt)2(pyr)] 4, 
[((C^N^C)Pt)2(4,4`-bipy)] 5 and [((C^N^C)Pt)2(dppb)] 6 (Figure 1). 
Compounds 1-6 were prepared using known or modified literature 
procedures.31-34 Compounds 1-5 were characterized by 1H NMR 
spectroscopy, mass spectrometry, FT-IR spectroscopy and 
elemental analysis and compound 1 was additionally 
characterized by 13C{1H} NMR spectroscopy.31-34 Compounds 2 
and 3 were additionally characterized by single crystal X-ray 
diffraction. and both complexes were confirmed to crystallize in the 
same crystal space group as the published literature 
structures.31,34 Additionally, 6 was characterized by 1H, 13C{1H} 
and 31P{1H} NMR spectroscopy, mass spectrometry, melting point 
analysis, FT-IR spectroscopy and single crystal X-ray diffraction. 
A singlet resonance is observed in the 31P{1H} NMR spectrum of 
6 at δ 20.3 ppm (JPPt = 4960 Hz) and is due to the two phosphines 
coupling with the platinum centers in this symmetric molecule.  
 
Figure 2. Molecular structure of complex 6. Hydrogen atoms have 
been omitted for clarity and displacement ellipsoids are at the 
50% probability level. Pt-P: 2.2190(17) – 2.2216(18) Å; Pt-N: 
2.022(5) – 2.0225(5) Å; and Pt-C: 2.076(6) – 2.091(6) Å and bond 
angles (ranging from 79.5(2) - 105.7(2) ˚). C atoms are shown in 
grey, N in light blue, Pt in white and P in orange.  
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Bright yellow crystals of 6 suitable for X-ray diffraction were 
obtained through the slow evaporation of a concentrated 
chloroform solution. The complex crystallizes in a monoclinic 
crystal system and solution refinement was performed in the 
space group P21/c (Table S1). The molecular structure of 6 is 
shown in Figure 2, with displacement ellipsoids placed at the 50 % 
probability level. All of the bond lengths and angles are 
representative of a pseudo square-planar geometry expected of 
d8 Pt(II) complexes (Tables S2 and S3).31 In the crystal packing 
of 6, there are intermolecular, edge-to-face, π-π stacking 
interactions present between the phenyl rings of dppb and 
aromatics of the C^N^C pincer ligand (Figure S1).35  
 
Chemoselectivity Studies  
Ligand 1, complexes 2-6, cisplatin (CDDP), oxaliplatin (OXA) and 
carboplatin (CARB) were all screened for their cytotoxicity against 
human cell lines: ovarian carcinoma (A2780), cisplatin-resistant 
ovarian carcinoma (A2780cisR) and breast adenocarcinomas 
(MCF-7 and MDA-MB-231). The IC50 values were obtained via the 
MTT assay after a 96 h incubation period of each compound with 
the cells at 37 °C and 5% CO2 (Table 1 and Figure 3). Ligand 1 
was found to be moderate to non-toxic against all cell lines, with 
IC50 values of 41 ± 2 M to > 100 M. The mononuclear 
platinum(II) complexes, 2 and 3, have significant differences in 
their cytotoxicity. The potency of complex 2 increases by up to 10-
fold against MCF-7 in comparison to ligand 1 (p < 0.05), and 
exhibits similar potency (IC50 = 4.4 ± 0.5 M) to CDDP (IC50 = 3.07 
± 0.02 M) against MDA-MB-231 (p = 0.01). Importantly, 2 is the 
only compound in this library which has noticeable toxicity 
towards MCF-7 (IC50 = 10 ± 1 M), however, it remains > 6-fold 
less cytotoxic than CDDP (p < 0.05). A recent report by Klein and 
co-workers determined that 2 has a IC50 value against MBA-MB-
231 of 12.12 ± 1.84 μM, which is slightly higher than our observed 
value.21 Furthermore, 2 is more active towards the cisplatin-
resistant ovarian cell line A2780cisR than the parental cisplatin-
sensitive A2780 cells. On replacing the monodentate  
Figure 3. Cytotoxicity values (IC50/ μM ± SD) for cisplatin (CDDP), oxaliplatin 
(OXA), carboplatin (CARB), ligand 1 and complexes 2-6 against human ovarian 
cancer (A2780, A2780cisR), human breast cancer (MCF-7, MDA-MB-231) and 
normal prostate cells (PNT2). 
DMSO ligand in 2 for PPh3 in 3, the activity significantly 
decreases, and 3 is non-toxic against all cell lines tested (IC50 
>100 M) (Table 1 and Figure 3).  
Complex 4 was designed to study the cytotoxicity effects of a 
dinuclear system with the short pyrazine linker. The cytotoxicity of 
4 increases by up to 27-fold and 5-fold against A2780 (p < 0.05), 
in comparison to mononuclear complexes 2 and 3, respectively. 
Upon extending the linker to 4,4`-bipy (5), the compound remains 
equitoxic to that of 4 against A2780, however, the toxicity 
decreases against all other cell lines, with up to a 2-fold decrease 
against A2780cisR and an 11-fold decrease against MDA-MB-
231 (p < 0.05). Harper et al. showed that the related 
[((N^N^N)Pt)2(4,4`-bipy)] (N^N^N = terpy) analogue of 5 has been 
reported to have GI50 values of 2.7 ± 1.3 μM against A2780 and 
5.6 ± 0.4 μM against A2780cisR.29  Whilst Lowe and co-workers 
 
Table 1. Cytotoxicity values (IC50/ μM ± SD) for cisplatin (CDDP), oxaliplatin (OXA), carboplatin (CARB), ligand 1 and complexes 2-6 after a 96 h incubation period 
with human ovarian carcinomas (A2780, A2780cisR), human breast adenocarcinomas (MCF-7, MDA-MB-231) and normal prostate cells (PNT2).[a] Selective Index 
(SI) values when compared to PNT2 are shown in parenthesis.  
 
Compounds 
IC50 values (μM) ± SD 
 A2780 A2780cisR MCF-7 MDA-MB-231 PNT2 
CDDP 1.3 ± 0.1 (6.4) 14 ± 1 (0.6) 1.5 ± 0.2 (5.6) 3.07 ± 0.02 (2.8) 8.5 ± 0.4 
OXA 0.505 ± 0.002 (2.6) 2.09 ± 0.03 (0.6) 2.6 ± 0.2 (0.5) 2.5 ± 0. 6 (0.5) 1.3 ± 0.2 
CARB 17 ± 1 (1.6) >100 (0.3) >100 (0.3*) 33 ± 2 (0.8) 27 ± 2 
1 >100 (n.d.) >100 (n.d.) >100 (n.d.) 41 ± 2 (2.5*) >100 
2 19.7 ± 0.5 (0.9) 13.9 ± 0.5 (1.3) 10 ± 1 (1.7) 4.4 ± 0.5 (4.0) 18 ± 1 
3 >100 (n.d.) >100 (n.d.) >100 (n.d.) >100 (n.d.) >100 
4 3.6 ± 0.4 (2.3) 9 ± 1 (1.0) 55 ± 2 (0.2) 1.9 ± 0.5 (4.4) 8.3 ± 0.6 
5 3.996 ± 0.002 (9.2) 18 ± 1 (2.0) >100 (0.4*) 22 ± 2 (1.7) 37 ± 2 
6 3.4 ± 0.4 (29.5*) 8.9 ± 0.5 (11.2*) >100 (n.d.) >100 (n.d.) >100 
[a] All values are averages from duplicate technical repeats and triplicate experimental repeats. * indicates the minimum SI value as at least one IC50 value is > 100 
μM. n.d. (not determined) indicates the values where both IC50 values are > 100 μM.
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reported that the same complex had IC50 values of > 25 μM 
against A2780 and 9.6 μM against A2780cisR.12a The differing 
IC50 values of 5 and the [((N^N^N)Pt)2(4,4`-bipy)] (N^N^N = terpy) 
analogue, highlights that the nature of the pincer ligand is also an 
important factor on determining the cytotoxicity of these 
cyclometallated platinum(II) complexes. On modification of the 
linker to a flexible butyl substituent, in the dinuclear diphosphine 
complex 6, the cytotoxicity against MDA-MB-231 decreases even 
further, with > 4-fold decrease when compared to 5 and > 52-fold 
decrease when compared to 4. Moreover, increasing the 
nuclearity of the platinum(II)-phosphine compounds from 
mononuclearity in 3 to dinuclearity in 6 generates a significant 
increase in the cytotoxicity of the compounds against the ovarian 
carcinoma cell lines with up to > 29-fold and > 11-fold increase 
observed against A2780 and A2780cisR, respectively. As the IC50 
values of 3 against both ovarian cancer cell lines, A2780 and 
A2780cisR, is greater than the tested threshold concentration of 
100 M, this observed increase in cytotoxicity between these two 
platinum(II)-phosphine ligands could be greater than reported 
here. As for 3, complex 6 is non-toxic against MCF-7 and MDA-
MB-231 (IC50 > 100 M). 
On analysis of these results, no definitive SARs can be 
determined, however, some important structural features can be 
highlighted; i) the nature of the ligand plays a significant role in 
determining the cytotoxicity of the mononuclear complexes, with 
the presence of the sulfoxide ligand in 2 increasing the potency in 
all test cancer cells lines by up to 25-fold compared to the 
analogous phosphine-platinum(II) complex 3 (e.g. 2 versus 3 
against MDA-MB-231), ii) the addition of a second platinum center 
and linker unit increases the potency of the compounds by up to 
29-fold (e.g. 3 versus 6 against A2780), iii) the shorter pyrazine 
linker in complex 4 is the optimal linker of the N-heterocyclic 
dinuclear species exhibiting up to sub-micromolar potency 
against MDA-MB-231 (IC50 = 1.9 ± 0.5 M). A notable result is 
that of complex 6, which is non-toxic towards either of the two 
human breast cancer cell lines (MCF-7 and MDA-MD-231, IC50 > 
100 M), has significantly increased cytotoxicity against the 
human ovarian cancer cell lines, >29-fold against A2780 (IC50 = 
3.4 ± 0.4 M, p < 0.05) and >11-fold against A2780cisR (IC50 = 
8.9 ± 0.5 M, p < 0.05). 
 
Selectivity Index (SI) 
Due to the current issues of the clinical platinum compounds 
(CDDP, OXA and CARB), which exhibit high potency towards 
normal cell types, this library of compounds were screened 
against normal prostate cell line, PNT2 (Table 1). As expected, 
the results highlight that the clinical platinum drugs are high to 
moderately cytotoxic towards this cell line, with IC50 values, 1.3 ± 
0.2 M (OXA), 8.5 ± 0.4 M (CDDP) and 27 ± 2 M (CARB). 
Ligand 1 and complex 3 are non-toxic towards PNT2 (IC50 > 100 
M). Complexes 2, 4 and 5 all remain moderately cytotoxic 
against the normal cell line, and even though complex 4 is > 4-
fold more cytotoxic against MDA-MB-231 than PNT2, it remains 
relatively cytotoxic against normal cells (IC50 = 8.3 ± 0.6 M). The 
most promising result is observed for 6, which remains non-toxic 
against PNT2 (IC50 > 100 M) yet is cytotoxic towards human 
ovarian carcinomas.  
The selectivity index (SI) values were calculated for all 
compounds, using the IC50 values obtained against PNT2 and 
dividing by the IC50 value against the cancer cell line (Table 1 and 
Figure 4). Whereby a SI value > 1 indicates increases selectivity  
Figure 4. Selectivity Index (SI) for CDDP, OXA, CARB, ligand 1 and complexes 
2-6 when the IC50 values of the cancerous lines are compared to those of the 
normal cell line PNT2. SI < 1 indicates selectivity the normal cell line PNT2,  SI  
= 1 indicates equitoxicity and SI > 1 indicates selectivity for the cancerous cell 
line. 
for the cancerous cell line over the normal cell line. Generally, 
compounds 1-4 do not have increased selectivity for A2780, 
A2780cisR and MCF-7, however, there are some notable  
increases in selectivity for the hormone independent breast 
adenocarcinoma cell line, MDA-MB-231, where complexes 2 and 
4 have SI of 4.0 and 4.4, respectively. Complex 5 displays a SI of 
9.2 and 2.0 against the ovarian carcinoma cell lines, A2780 and 
A2780cisR respectively, which outperforms CARB by 5.8-fold 
(A2780) and 6.7-fold (A2780cisR) (Table 1). Unlike 4, complex 5 
does not have increased selectivity towards MDA-MB-231. The 
most promising result is observed for complex 6 against the 
ovarian cell lines, with SI values of > 29.5 and > 11.2 for A2780 
and A2780cisR, respectively. These results are also minimum SI 
values, as the IC50 value against PNT2 is greater than the tested 
threshold concentration of 100 M, and so the SI could be greater 
than reported here. Cisplatin has a high SI against A2780 (SI = 
6.4), however, 6 exhibits a SI value of 29.5, which is 4-fold higher 
than that of CDDP (p < 0.05). Importantly, the SI values observed 
for complex 6 against A2780cisR show a higher degree of 
selectivity than the clinical platinum compounds, with SI values > 
18-fold (CDDP and OXA) and > 42-fold (CARB). 
 
Resistance and Sensitivity Factors 
As many cancers become resistance to drugs, including the 
clinical platinum drugs, there is an urgent need to address the 
issues of drug resistance, by designing new and effective drugs. 
To address the potential of compounds 1-6 to target the ovarian 
cisplatin-resistance cell line A2780cisR, the IC50 values were 
compared with those from the ovarian cisplatin-sensitive cell line 
A2780. RF values > 1 indicate a preference for the cisplatin 
resistant cell line A2780cisR. The RF values could not be 
calculated for ligand 1 and complex 3, as IC50 values are > 100 
M against both ovarian cell lines. As with the clinical platinum 
drugs, complexes 4-6 are all more cytotoxic towards A2780. 
However, complex 2 has a slightly higher selectivity for 
A2780cisR, with a RF value of 1.4 (Figure S2).  
To address the activity of compounds 1-6 in comparison with the 
clinical drugs, the sensitivity factors (SF) were calculated by 
dividing the IC50 values of the clinical drugs by the IC50 values of 
compounds 1-6. An SF > 1 indicates a selectivity for our library of  
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Figure 5. Sensitivity factor (SF) for ligand 1 and complexes 2-6 when the IC50 
values are compared with A. cisplatin (CDDP), B.  oxaliplatin (OXA) and C. 
carboplatin (CARB). 
compounds over the clinical drugs (Figure 5). When comparing 
the performance of our library of compounds with CDDP (Figure 
5A), complexes 4 and 6 are 1.6x more cytotoxic against MDA-
MB-231 (4) and A2780cisR (4 and 6) whilst the rest of the library 
displays SF < 1 against the other tested cell lines. When the 
biological performance of 1-6 is compared to OXA (Figure 5B), 
only complex 4 is more cytotoxic, and is 1.3x more active against 
MDA-MB-231. The most promising results are observed when 
comparing the cytotoxicity values of the library with CARB, 
wherein complexes 2, 4-6 are markedly more cytotoxic than this 
clinical drug against a range of the tested cell lines (Figure 5C). 
In particular, complexes 2 and 4 have high selectivity for MDA-
MB-231, with IC50 values 7.4x and 17.0x higher than CARB, 
respectively. Triple negative breast cancers (TNBC) are the most 
complex and aggressive types of breast cancer,36 and are 
associated with high metastasize, patient relapse, poor prognosis 
and low survival rates. Therefore, designing and identifying drugs 
which are effective against these cancers is essential and urgent. 
Since several of our compounds have promising high activities 
against MDA-MB-231, this warrants further investigation into their 
use against TNBC. Complexes 2, 4-6 all have increases activity 
towards one or more of the ovarian carcinomas, when compared 
to CARB, with significantly higher activity against A2780 
displaying SF ranging from 4.3 (5) to 5 (6) and, notably, against 
the cisplatin-resistance ovarian cell line A2780cisR, with SF 
ranging from 5.4 (5) to 11.4 (4). Additionally, complex 2 has 
significantly higher activity when compared to CARB against the 
breast adenocarcinoma MCF-7, displaying an IC50 value at least 
10x higher than this clinical drug.37  
Together, these results highlight the significant cytotoxic potential 
for this library of compounds, especially for the dinuclear 
complexes 4 and 6. Although complex 4 is moderately cytotoxic 
towards the normal cell line, its increased selectivity towards the 
TNBC line MDA-MB-231 is promising and should be investigated 
in further studies. Complex 6 is non-toxic towards the normal cell 
line and has the highest cancer cell selectivity for this library, 
warranting further modifications and in-depth in vitro studies. On 
analysis of these results, it is possible that these complexes have 
mechanism of actions which differs from that of the clinical 
platinum drugs. As it has previously been shown that 
cyclometallated N^N^N platinum(II) cationic complexes form 
strong intercalations with DNA, with binding constants from 0.8 x 
105 M-1 to 2.0 x 107 M-1,38,39 it is possible that the compounds 
reported herein have the potential to exert their potency through 
a similar manner. In order to further develop this library of 
compounds, it is now necessary to obtained sufficient SARs and 
a more in-depth in vitro screening, to underpin the cellular uptake 
and possible mechanisms of action of such diplatinum species. 
Conclusion 
In conclusion, we have synthesized a library of mono- and di-
nuclear, cyclometallated platinum(II) complexes, of the general 
formula, [(C^N^C)Pt(II)(L)] and [((C^N^C)Pt(II))2(L`)] respectively, 
where H^C^N^CH is 2,6-diphenylpyridine, L is a monodentate 
ligand (DMSO 2 or PPh3 3) and L` is a bidentate ligand (pyr 4, 
4,4`-bipy 5 or dppb 6). All compounds were screened against 
human ovarian carcinomas (A2780 and A2780cisR), human 
breast adenocarcinomas (MCF-7 and MDA-MB-231) and normal 
prostate cell line (PNT2). There are no definite conclusions which 
can be drawn on the SARs however, some general trends can be 
observed.  
Firstly, comparing the mononuclear complexes, platinum(II)-
sulfoxide 2 and platinum(II)-phosphine 3, the nature of the 
monodentate ligand at the fourth coordination site of the metal 
center strongly influences the antiproliferative activity of the 
complex. The former displaying significantly increased potency 
against all tested cancer cell lines (IC50 = 4.4 - 19.7 μM) compared 
to 3 which is non-toxic (IC50 >100 μM).  
Secondly, shortening the length of the linker between the two 
metal centers in these cyclometallated platinum(II) complexes 
from pyr in 4 to 4,4`-bipy in 5, has a significant effect on increasing 
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the cytotoxicity of the complex, by up to 11-fold, against three of 
the tested cancer cell lines (A2780cisR, MCF-7 and MDA-MB-
231). 
Thirdly, there is general increase in potency observed for the 
dinuclear complexes 4-6 when compared to the mononuclear 
complexes 2 and 3. For the platinum(II)-phosphine complexes 3 
and 6, the latter dinuclear complex showed significantly increased 
cytotoxicity against the ovarian carcinoma cell lines with up to > 
29-fold and > 11-fold increase observed against A2780 and 
A2780cisR, respectively when compared to mononuclear 
complex 3. 
Several of the studied complexes are more cytotoxic than the 
clinical drug, carboplatin (CARB), with cytotoxicity values up to 
7.4x (2) and 17.0x (4) against the TNBC line, MDA-MB-231. This 
is important in the development of breast cancer drugs, as this is 
the most complex and aggressive form of breast cancer. 
Generally, these cyclometallated complexes have increased 
activity towards ovarian carcinomas (cf. to CARB) with 
significantly higher activity against the cisplatin-resistance ovarian 
cell line A2780cisR, with sensitivity factors (SF) ranging from 5.4 
(5) to 11.4 (4). Notably, complex 6 was non-toxic towards the 
normal cell line (IC50 > 100 M) and has selectivity index (SI) 
values > 29 against A2780 and is up to 42-fold more selective 
than current clinical platinum drugs. 
We have identified the dinuclear platinum(II)-phosphine complex 
6 as the lead candidate of the studied library, as it remains non-
toxic towards the normal cell line, and our future work will now be 
aimed at underpinning the specific mechanisms of action of this 
complexes. We anticipate that the insights gained from this 
systematic study will continue to help inform the future design of 
novel cyclometallated diplatinum(II) complexes with high in vitro 
potential. 
Experimental Section 
General Experimental Details 
All NMR spectroscopy was carried out on a Bruker Advance 400 FT NMR 
spectrometer using the residual solvent as the internal standard. All the 
chemical shifts (δ) are quoted in ppm and coupling constants are given in 
Hz and are rounded to 0.1 Hz. Melting points were obtained on 
GallenKemp and are uncorrected. Single crystal X-ray diffraction data on 
2, 3 and 6 was collected using a Bruker X8 diffractometer with an APEX II 
detector and monochromated Mo Kα radiation (λ  = 0.7107 Å) at 173 K. 
The data was processed using Bruker SAINT, the structures determined 
with SHELXT40 and subsequently refined with SHELXL41 within the 
program olex2.42 Crystal structures were visualised using Mercury.43 
Infrared spectroscopy was carried out on a Perkin Elmer 100 FT-IR 
instrument fitted with an ATR detector. Mass spectrometry was recorded 
on a Waters Micromass Quattro Ultima quadrupole mass spectrometer at 
the Bradford Analytical Centre. All the reactions were conducted under 
nitrogen atmosphere. Potassium carbonate, sodium carbonate, 
concentrated aqueous ammonia and acetic acid were purchased from 
Camlab. Dimethylsulfoxide, toluene, methanol, dichloromethane, 
petroleum ether, di-ethyl ether and chloroform were purchased from Fisher. 
Tetrakis(triphenylphosphine)palladium(0), 2,6-dibromopyridine, 
triethylamine, 4-phenylboronic acid, pyrazine, 4,4`-bipyridine, 
triphenylphosphine, 1,4-bis(diphenylphosphino)butane and potassium 
tetrachloroplatinate were purchased from Sigma Aldrich. Petrol refers to 
the fraction of light petroleum ether boiling between 40 and 60 °C. All 
chemicals were used as received unless otherwise stated. The following 
abbreviations are employed: 4,4`-bipy = 4,4`-bipyridine, aq. = aqueous, Ar 
= aromatic, br = broad, calc. = calculated, CARB = carboplatin, CDDP = 
cisplatin, d = doublet, DMSO = dimethylsulfoxide, dppb = 1,4-
bis(diphenylphosphino)butane, eq. = equivalent(s), Et = ethyl, h = hour(s), 
Hz = Hertz, IC50 = half maximal inhibitory concentration, IR = infrared, m = 
multiplet, Me = methyl, m.p. = melting point, MTT = 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide, OXA = oxaplatin, pet. = petroleum, 
Ph = phenyl, pyr = pyrazine, s = singlet, SD = standard deviation, SI = 
selectivity index, terpy = terpyridine, TNBC = triple negative breast cancer 
and t = triplet. Compounds 1-5 were synthesised according to known 
literature procedures. 31-33 
Cell culture  
In vitro chemosensitivity tests were performed against human ovarian 
carcinoma (A2780), cisplatin-resistant human ovarian carcinoma 
(A2780cis) and human breast adenocarcinomas (MCF-7 and MDA-MB-
231). Additionally, growth inhibitory effects were also tested against 
normal prostate cell line, PNT2. All cell lines were provided by the Institute 
of Cancer Therapeutics, University of Bradford and were routinely 
maintained as monolayer cultures in RPMI 1640 media supplemented with 
10% foetal calf serum, sodium pyruvate (1 mM) and L-glutamine (2 mM). 
All assays were conducted in 96-well round bottom plates, with control 
lanes for media and 100% cell growth. Cell concentrations of 1 x 104 
cells/mL were used, and 100 µL (or 100 µL media in control lane 1) of cell 
suspension were incubated for 24 hours at 37 °C and 5% CO2 prior to drug 
exposure. Ligand 1, complexes 2-6, cisplatin (CDDP), oxaliplatin (OXA) 
and carboplatin (CARB) were all dissolved in dimethylsulfoxide to provide 
100 mM stock solutions, which were further diluted with complete media 
to provide a range of final concentrations. After 24 hours incubation, 100 
μL of the drug/media solutions were added to the plates in columns 3-12 
(100 µL media in lanes 1 and 2 for controls), and then the plates incubated 
for 96 hours at 37°C and 5% CO2. Drug solutions were added to cells so 
that the final DMSO concentrations were less than 0.1% (v/v) in all cases. 
After 96 hours, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) (20 µL, 5 mg/mL) was added to each well and incubated 
for 3 hours at 37 °C and 5% CO2. All solutions were then removed via 
pipette and 150 μL DMSO added to each well in order to dissolve the 
purple formazan crystals. A Thermo Scientific Multiscan EX microplate 
photometer was used to measure the absorbance of each well at 540 nm. 
Percentage cell viabilities were determined on a logarithmic scale, and the 
half maximal inhibitory concentration (IC50) determined from a plot of % 
cell survival versus concentration (µM). Each of the experiments was 
performed as duplicate technical repeats and triplicate experimental 
repeats, with mean values as the IC50 ± Standard Deviation (SD). 
Statistical Analysis  
A two-tailed ANOVA t-test has been conducted using Graph Pad Prism 8, 
and used to compare all chemosensitivity data: probability values p < 0.05 
are considered significant.  
Synthetic Details  
1: A solution of 2,6-dibromopyridine (2.0 g, 8.4 mmol) and Pd(Ph3)4 (0.39 
g, 0.34 mmol) in toluene (28 mL) was treated with a solution of Na2CO3 
(3.6 g, 34 mmol) in H2O (17 mL). A solution of 4-phenylboronic acid (4.1 g, 
34 mmol) in methanol (35 mL) was then added to this two phase system 
and the reaction mixture stirred at 85 ˚C for 16 h. Upon cooling to room 
temperature, concentrated aqueous NH3 (4 mL) and sat. Na2CO3 (40 mL) 
were added and the aqueous phase was extracted with dichloromethane 
(3 × 30 mL). The organic washings were combined and washed with brine, 
dried over MgSO4 and concentrated down under reduced pressure. The 
resulting residue was subjected to flash column chromatography (2:98; 
Et2O:pet. ether) and crystals were grown through recrystallization from 
methanol and Et2O. (1.9 g, 77%). 1H NMR (400 MHz, CDCl3, 298 K): δ 
8.17-8.14 (4H, m, ArH), 7.83 (1H, t, 3J = 8.0 Hz, ArH), 7.70 (2H, dd, 3J = 
8.0 Hz, 4J  = 0.4 Hz, ArH), 7.53-7.48 (4H, m, ArH), 7.45-7.41 (2H, m, ArH), 
13C{1H} NMR (100 MHz, CDCl3, 298 K): δ 156.8, 139.5, 137.5, 129.0, 
128.7, 127.0, 118.6; IR (solid) νmax 3058 (w), 3027 (w), 1573 (m), 1562 (m) 
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cm-1; LR-ESIMS (+ve) m/z (%): 232 [M+H]+ (100%); HR-ESIMS (+ve): 
calcd. 232.1121 found 232.1115 for C17H14N. Elemental Analysis: Anal. 
Found: C: 88.2, H: 5.7, N: 6.1%. Anal. Calculated: C: 88.3, H: 5.7, N: 6.1%. 
2: To a solution of H2L (0.30 g, 1.3 mmol) in acetic acid (55 mL) was added 
a solution of K2PtCl4 (0.54 g, 1.3 mmol) in H2O (3 mL) in a dropwise 
manner to generate a light rose coloured solution. The mixture was 
refluxed for 18 h, after which time, the red colour of the Pt salt had 
disappeared. The yellow precipitate that had formed was filtered off and 
washed with H2O (4 mL), acetone (4 mL), Et2O (4 mL) and pet. ether (2 
mL). The yellow solid was then dissolved in DMSO (3 mL) and K2CO3 (0.75 
g, 5.4 mmol) and H2O (2 mL) were added and the mixture heated to 90 ˚C 
for 1 h. After this time, the reaction mixture was allowed to cool to room 
temperature and upon the addition of H2O (10 mL), the product 
precipitated out as a bright yellow solid. This crude product was subjected 
to flash column chromatography (CH2Cl2). Single bright yellow crystals 
suitable for X-ray diffraction were grown through the slow evaporation of 
chloroform from a saturated solution of 2. (0.27 g, 41%). 1H NMR (400 
MHz, CDCl3, 298 K): δ 7.81 (2H, dd, 3J = 7.2 Hz, 4J = 0.8 Hz, J(195Pt) = 
29.6 Hz, ArH), 7.63 (1H, t, 3J = 8.0 Hz, ArH), 7.49 (2H, dd, 3J = 7.6 Hz, 4J 
= 1.2 Hz, ArH),  ArH), 7.33 – 7.27 (4H, m, ArH), 7.13 (2H, dt, 3J = 7.2 Hz, 
4J  = 1.2 Hz, ArH), 3.69 (6H, s, J(195Pt) = 27.2 Hz, 2 × CH3); IR (solid) νmax 
3034 (w), 2920 (w), 1598 (m), 1577 (m), 1562 (m) cm-1; LR-ESIMS (+ve) 
m/z (%): 503 [M+H]+(100%); HR-ESIMS (+ve): calcd. 503.0751 found 
503.0745 for C19H18NO2NaPtS. Elemental Analysis: Anal. Found: C: 45.6, 
H: 3.3, N: 2.8%. Anal. Calculated: C: 45.4, H: 3.4, N: 2.8%. 
3: To a solution of 2 (0.050 g, 0.10 mmol) in CH2Cl2 (2 mL) was added 
PPh3 (0.026 g, 0.10 mmol) and the resultant pale-yellow solution was 
stirred at ambient temperature for 1 min. After this time, the excess solution 
was removed under reduced pressure and the resulting yellow residue was 
subjected to flash column chromatography (1:1:0.01; CH2Cl2:pet. 
ether:NEt3) to yield a bright yellow solid. Single crystals suitable for X-ray 
crystallography were grown through the slow diffusion of di-ethyl ether into 
a saturated solution of 3 in chloroform. (0.025 g, 37%). 1H NMR (400 MHz, 
DMSO-d6, 298 K): δ 7.94 (1H, t, 3J = 7.6 Hz, ArH), 7.85 – 7.80 (6H, m, 
ArH), 7.73 (2H, dd, 3J = 8.4 Hz, 4J = 1.6 Hz, ArH), 7.62 (2H, dd, 3J = 8.0 
Hz, 4J = 1.2 Hz, ArH), 7.60 – 7.51 (9H, m, ArH), 6.93 (2H, dt, 3J = 7.2 Hz, 
4J = 1.2 Hz, ArH), 6.62 (2H, dt,  3J = 7.6 Hz, 4J = 1.6 Hz, ArH), 6.18 (2H, d, 
3J = 7.6 Hz, J(195Pt) = 32.4 Hz, ArH); IR (solid) νmax 3040 (w), 1597 (m), 
1563 (m), 1508 (w) cm-1; LR-ESIMS (+ve) m/z (%): 687 [M+H]+(100%); 
Elemental Analysis: Anal. Found: C: 61.1, H: 3.7, N: 2.1%. Anal. 
Calculated: C: 61.2, H: 3.8, N: 2.0%. 
4: To a solution of 2 (0.050 g, 0.10 mmol) in CH2Cl2 (2 mL) was added 
pyrazine (0.039 g, 0.050 mmol) and the resultant pale-yellow solution was 
stirred at ambient temperature overnight. After this time, the red precipitate 
that had formed was filtered off, washed with CH2Cl2 (2 mL) to give the 
desired product as a bright red solid. (0.002 g, 4%). 1H NMR (400 MHz, 
DMSO-d6, 298 K): δ 8.65 (4H, s, ArH), 7.84 (2H, t, 3J = 8.4 Hz, ArH), 7.76 
(4H, dd, 3J = 7.2 Hz, 4J = 0.8 Hz,  ArH), 7.65 – 7.63 (8H, m, ArH), 7.19 (4H, 
dt, J = 7.6 Hz, 4J  = 1.2 Hz, ArH), 7.08 (4H, d, 3J = 7.6 Hz, ArH); IR (solid) 
νmax 3043 (w), 1697 (w), 1598 (m), 1575 (m), 1560 (m) cm-1; LR-ESIMS 
(+ve): 929 [M+H]+ (100%); Elemental Analysis: Anal. Found: C: 49.0, H: 
2.8, N: 6.0%. Anal. Calculated: C: 49.1, H: 2.8, N: 6.0%. 
5: To a solution of 2 (0.050 g, 0.10 mmol) in CH2Cl2 (2 mL) was added 
4,4`-bipyridine (0.0080 g, 0.050 mmol) and the resultant pale-yellow 
solution was stirred at ambient temperature overnight. After this time, the 
red precipitate that had formed was filtered off, washed with CH2Cl2 (2 mL) 
to give the desired product as a bright orange solid. (0.03 g, 58%). 1H NMR 
(400 MHz, DMSO-d6, 298 K): δ 8.73 (4H, dd, 3J = 6.0 Hz, 4J = 0.4 Hz, ArH), 
7.84 – 7.82 (6H, m, ArH), 7.77 (4H, dd, 3J = 7.6 Hz, 4J = 1.2 Hz, ArH), 7.66 
– 7.63 (8H, m, ArH), 7.20 (4H, dt, 3J = 7.6 Hz, 4J = 1.6 Hz, ArH), 7.08 (4H, 
dt, 3J = 7.6 Hz, 4J = 1.2 Hz, ArH); IR (solid) νmax 3041 (w), 1597 (m), 1575 
(m), 1558 (m), 1541 (m) cm-1; LR-ESIMS (+ve): 1005 [M+H]+; Elemental 
Analysis: Anal. Found: C: 51.9, H: 3.0, N: 5.4%. Anal. Calculated: C: 52.6, 
H: 3.0, N: 5.6%. 
6: To a solution of 2 (0.050 g, 0.095 mmol) in CH2Cl2 (2 mL) was added 
dppb (0.021 g, 0.048 mmol) and the resultant pale-yellow solution was 
stirred at ambient temperature for 1 h. After this time, the pale-yellow 
precipitate that had formed was filtered off and yellow crystals suitable for 
X-ray diffraction were grown through the slow diffusion of pet. ether into a 
saturated solution of chloroform (0.015 g, 12%). m.p. 310-311 °C; 1H NMR 
(400 MHz, CD2Cl2, 298 K): δ 7.70-7.65 (10H, m, ArH), 7.44 (4H, dd, 3J = 8 
Hz, 4J = 1.2 Hz, ArH), 7.38-7.28 (16H, m, ArH), 6.93 (4H, dt, 3J = 8 Hz, 4J 
= 1.2 Hz, ArH), 6.70 (4H, dt, J = 8 Hz, 4J = 1.2 Hz, ArH), 6.55 (4H, d, 3J = 
8 Hz, 195J = 12 Hz, ArH), 2.62-2.55 (4H, s, CH2), 2.01-1.99 (4H, s, CH2); 
13C{1H}  NMR (100 MHz, CD2Cl2, 298 K): δ 165.7 (JC-Pt = 104 Hz), 150.2, 
139.6, 138.0 (JC-Pt = 116 Hz), 132.6, 132.5 (JC-Pt = 100 Hz), 129.5, 129.1, 
127.5, 127.4, 123.2, 122.7, 114.2, 25.7, 25.3; 31P NMR (162 MHz, CD2Cl2, 
298 K): δ 20.3 (JP-Pt = 4960 Hz); IR (solid) νmax 3047 (w), 2936 (w), 2918 
(w), 1597 (m), 1578 (m), 1565 (m), 1546 (m); LR-ESIMS (+ve): 1275 
[M+H]+; 1297 [M+Na]+; HRESI (+ve): calcd. 1275.2823 found 1275.2803 
for C62H51N2P2Pt2; calcd. 1297.2642 found 1297.2637 for 
C62H50N2NaP2Pt2.  
Acknowledgements  
We are grateful to the University of Bradford’s Analytical Centre 
for support, in particular Haseeb Ul-Rehman for conducting mass 
spectrometry experiments. We would like to thank the Institute of 
Cancer Therapeutics, University of Bradford for access to Cat II 
laboratories and providing cell lines. We acknowledge Stephen 
Boyer (London Metropolitan University) for conducting the 
elemental analysis. R.M.L. and S.J.P. thank the University of 
Bradford Research Fund for financial support. S.J.P. is a UKRI 
Future Leaders Fellow, and this work was supported by a UKRI 
Future Leaders Fellowship [MR/S035486/1].  
Keywords: anticancer • bioinorganic chemistry • cyclometallated 
platinum(II) •  multinuclear complexes • phosphine ligands 
[1] (a) T. Makovec, Radiol. Oncol. 2019, 53, 148-158; (b) B. Rosenberg, L. 
VanCamp, J. E. Trosko, V. H. Mansour, Nature 1969, 222, 385-386. 
[2] (a) K. S. Lovejoy, S. J. Lippard, Dalton Trans. 2009, 48, 10651-10659; 
(b) D. –W. Shen, L. M. Pouliot, M. D. Hall, M. M. Gottesman, 
Pharmacological Rev. 2012, 64, 706-721; (c) C. Meijer, N. H. Mulder, H. 
Timmer-Bosscha, W. J. Sluiter, G. J. Meersma, E. G. E. de Vries, Cancer 
1992, 52, 6885-6889; (d) R. Oun, Y. E. Moussa, N. J. Wheate, Dalton 
Trans. 2018, 47, 6645-6653. 
[3] (a) T. C. Johnstone, K. Suntharalingam, S. J. Lippard, Chem. Rev. 2016, 
116, 3436-3486; (b) P. C. A. Bruijninex, P. J. Sadler, Curr. Opin. Chem. 
Biol. 2008, 12, 197-206; (c) D. Wang, S. J. Lippard, Nat. Rev. Drug 
Discovery 2005, 4, 307-320; (d) P. Zhang, P. J. Sadler, J. Organomet. 
Chem. 2017, 839, 5-14. 
[4] K. M. Deo, D. L. Ang, B. McGhie, A. Rajamanickam, A. Dhiman, A. 
Khoury, J. Holland, A. Bjelosevic, B. Pages, C. Gordon, J. R. Aldrich-
Wright, Coord. Chem. Rev. 2018, 375, 148-163. 
[5] I. Omae, Coord. Chem. Rev. 2014, 280, 84-95. 
[6] C. –M. Che, M. Yang, K. –H. Wong, H. –L. Chan, W. Lam, Chem. Eur. J. 
1999, 5, 3350-3365. 
[7] N. Cutillas, G.  S. Yellol, C. de Haro, C. Vicente, V. Rodríguez, J. Ruiz, 
Coord. Chem. Rev., 2013, 257, 2784-2797. 
[8] Selected examples: (a) A. G. Quiroga, L. Cubo, P. J. S. Miguel, V. Moneo, 
C. Carnero, C. Navarro-Ranniger, Eur. J. Med. Chem. 2008, 8, 1183-
1187; (b) A. G. Quiroga, J. M. Pérez, I. Lόpez-Solera, J. R. Masaguer, A. 
Luque, P. Román, A. Edwards, C. Alonso, C. Navarro-Ranninger, J. Med. 
Chem. 1998, 41, 1399-1408; (c) J. Quirante, D. Ruiza, A. Gonzalez, C. 
López, M. Cascante, R. Cortés, R. Messeguer, C. Calvis, L. Baldomà, A. 
Pascual, Y. Guérardel, B. Pradines, M. Font-Bardía, T. Calvet, C. Biot, J. 
Inorg. Biochem., 2011, 105, 1720-1728. 
[9]    Selected examples: (a) R. Cortés, M. Crespo, L. Davin, R. Martín, J. 
Quirante, D. Ruiz, R. Messeguer, C. Clavis, L. Baldomà, J. Badia, M. 
Font-Bardía, T. Calvet, M. Cascante, Eur. J. Med. Chem. 2012, 54, 557-
556; (b) T. Zu, J. Liu, C. T. Lum, C. Ma, R. C. –T. Chan, C. –N. Lok, W. 
–M. Kwok, C. –M. Che, Angew. Chem. Int. Ed. 2014, 53, 10119-10123; 
(c) J. L. –L. Tsia, T. Zou, J. Liu, T. Chen, A. O. –Y. Chan, C. Yang, C. –
10.1002/chem.202002517
Ac
ce
pt
ed
 M
an
us
cr
ip
t
Chemistry - A European Journal
This article is protected by copyright. All rights reserved.
FULL PAPER    
8 
 
N. Lok, C. –M. Che, Chem. Sci. 2015, 6, 3823-3830; (d) R. Martín, M. 
Crespo, M- Font-Bardía, T. Calvet, Organometallics, 2009, 28, 587-597.  
[10] D. A. K. Vezzu, Q. Lu, Y.-H. Chen, S. Huo, J. Inorg. Biol., 2014, 134, 49-
56. 
[11]    Selected examples: (a) K. Li, T. Zou, Y. Chen, X. Guan, C. –M. Che, 
Chem. Eur. J. 2015, 21, 7441-7453; (b) Z. Ou, Z. Feng, G. Liu, Y. Chen, 
Y. Gao, Y. Li, X. Wang, Chem. Lett., 2015, 44, 425-427; (c) K. Wang,  C. 
Zhu, Y. He, Z. Zhang, W. Zhou, N. Muhammad, Y. Guo, X. Wang, Z. Guo, 
Angew. Chem. Int. Ed., 2019, 58, 4638-4643. 
[12] (a) G. Lowe, A. S. Droz, T. Vilaivan, G. W. Weaver, J. J. Park, J. M. Pratt, 
L. Tweedale, L. R. Kelland, J. Med. Chem., 1999, 42, 3167-3174, (b) K. 
Becker, C. Herold-Mende, J. J. Park, G. Lowe, R. H. Schirmer, J. Med. 
Chem., 2001, 44, 2784-2792. 
[13] B. W. J. Harper, T. T. Morris, J. Gailer, J. R. Aldrich-Wright, J. Inorg. 
Biochem., 2016, 163, 95-102.  
[14]     K. Choroba, B. Machura, L. R. Raposo, J. G. Małecki, S. Kula, M. Pajak, 
K. Erfurt, A. M. Maroń, A. R. Fernandes, Dalton Trans., 2019, 48, 13081-
13093. 
[15]     A. Savić, T. Marzo, F. Scaletti, L. Massai, G. Bartoli, R. Hoogenboom, L. 
Messori, R. Van Deun, K. Van Hecke, Biometals, 2019, 32, 33-47. 
[16]     S. Wang,  W. Chu,  Y. Wang,  S. Liu,  J. Zhang,  S. Li,  H. Wei,  G. Zhou,  
X. Qin, Appl. Organomet. Chem., 2013, 27, 373-379. 
[17]     C. Li, F. Xu, Y. Zhao, W. Zheng, W. Zeng, Q. Luo, Z. Wang, K. Wu, J.    
  Du, F. Wang, Front Chem., 2020, doi.org/10.3389/fchem.2020.00210. 
[18]   D. -L. Ma, T. Y. -T. Shum,   F. Zhang, C. -M. Che, M. Yang, Chem. 
Commun., 2005, 4675-4677.  
[19]    J. Dinda, S. D. Adhikary, G. Roymahapatra, K. K. Nakka, M. K. Santra, 
Inorg. Chim. Acta 2014, 413, 23-31. 
[20]     H Shi, G. J. Clarkson, P. J. Sadler, Inorg. Chim. Acta 2019, 489, 230-
235. 
[21] S. Garbe, M. Krause, A. Klimpel, I. Neundorf, P. Lippmann, I. Ott, D. 
Brünink, C. A. Strassert, N. L. Doltsinis, A. Klein, Organometallics, 2020, 
39, 746-756. 
[22]     (a) N. J. Wheate, J. G. Collins, Coord. Chem. Rev., 2003, 241, 133-145; 
(b) N. P. Farrell, Chem. Soc. Rev. 2015, 44, 8773-8785; (c) S. Komeda, 
M. Lutz, A. L. Spek, M. Chikuma, J. Reedijk, Inorg. Chem. 2000, 39, 
4230-4236. 
[23]     T. W. Failes, M. D. Hall, T. W. Hambley, Dalton Trans. 2003, 1596-1600. 
[24] R. W. -Y. Sun, A. L. -F. Chow, X. -H. Li, J. J. Yan, S. S. -Y. Chui, C. -M. 
Che, Chem. Sci., 2011, 2, 728-736. 
[25] C. Alexander, N. U. Prajith, P. V. Priyanka, A. Nithyakumar, N. A. Samy, 
J. Inorg. Biol., 2019, 24, 405-418. 
[26]    (a) T. C. Johnstone, G. Y. Park, S. J. Lippard, Anticancer Res. 2014, 34,  
471-476; (b) S. D. Brown, K. D. Trotter, O. B. Sutcliffe, J. A. Plumb, B.  
Waddell, N. E. B. Briggs, N. J. Wheate, Dalton Trans. 2012, 41, 11330. 
[27]     H. –L. Chan, D. –L. Ma, M. Yang, C. –M. Che, ChemBioChem. 2003, 4, 
62-68. 
[28] C. Navarro-Ranninger, I. López-Solera, V. M. González, J. M. Pérez, A. 
Alvarez-Valdés, A. Martín, P. R. Raithby, J. R. Masaguer, C. Alonso, 
Inorg. Chem., 1996, 35, 5181-5187. 
[29] B. W. J. Harper, J. R. Aldrich-Wright, Dalton Trans., 2015, 44, 87-96. 
[30] S. W. Lai, M. C. W. Chan, T. C. Cheung, C. -M. Che, Inorg. Chem., 1999, 
38, 4046-4055. 
[31]    G. W. V. Cave, N. W. Alcock, J. P. Rourke, Organometallics 1999, 18, 
1801. 
[32] W. Lu, C. W. Chan, K. -K. Chenug, C. -M. Che, Organometallics 2001, 
20, 2477-2486.  
[33] P. J. Lusby, P. Müller, S. J. Pike, A. M. Z. Slawin, J. Am. Chem. Soc. 
2009, 131, 16398-16400. 
[34] M. Baya, U. Belío, I. Fernández, S. Fuertes, A. Martín, Angew. Chem. 
Int. Ed. 2016, 55, 6978-6982. 
[35]      C. Hunter, J. Singh and J. Thornton, J. Chem. Soc. Perkin Trans. 2 2001, 
651. 
[36] V. Thakur, R. V. Kutty, J. Exp. Clin. Cancer Res., 2019, 38, 430-452. 
[37]    This result is based on minimum SI values, as the IC50 value against 
CARB is greater than the tested threshold concentration of 100 μM, and 
so the SI could be greater than reported here. 
[38]     K. W. Jenette, S. J. Lippard, G. A. Vassiliades, W. R. Bauer, Proc. Nat. 
Acad. Sci. USA, 1974, 71, 3839.  
[39] A. McCoubrey, H. C. Latham, P. R. Cook, A. Rodger, G. Lowe, FEBS 
Lett., 1996, 380, 73. 
[40] G. M. Sheldrick, Acta Crystallogr. Sect. A:, 2015, 71, 3-8. 
[41] G. M. Sheldrick, Acta Crystallogr. Sect. A, 2008, 64, 112-122. 
[42] O. V. Dolomanov, L. J. Bourhis, R. J.  Gildea, J. A. K. Howard, H. 
Puschmann, J. Appl. Cryst., 2009, 42, 339-341. 
[43]      (a) C. F. Macrae, I. J. Bruno, J. A. Chisholm, P. R. Edgington, P. McCabe, 
E. Pidcock, L. Rodriguez-Monge, R. Taylor, J. van de Streek, P. A. Wood, 
J. Appl. Cryst., 2008, 41, 466-470; (b) C. F. Macrae, P. R. Edgington, P. 
McCabe, E. Pidcock, G. P. Shields, R. Taylor, M. Towler, J. van de 
Streek, J. Appl. Cryst., 2006, 39, 453-457. 
 
 
10.1002/chem.202002517
Ac
ce
pt
ed
 M
an
us
cr
ip
t
Chemistry - A European Journal
This article is protected by copyright. All rights reserved.
FULL PAPER    
9 
 
 
Entry for the Table of Contents 
  
 
A study of the cytotoxicity of a library of cyclometallated mono- and di-nuclear platinum(II)-complexes, against a range of ovarian and 
breast cancer cell lines, identifies the importance of both ligand type and nuclearity on their antiproliferative activity. The lead 
candidate, a di-nuclear platinum(II)-phosphine complex, exhibits very high selectivity towards cancerous cells, with a selectivity index 
(SI) value > 11.2 against cisplatin-resistant ovarian cancer cells and outperforming monodentate analogues by > 11-fold and cisplatin 
by > 18-fold. 
Institute and/or researcher Twitter usernames: @chemistry_lord  @UoBChem  @UEA_Chemistry, @chembham 
10.1002/chem.202002517
Ac
ce
pt
ed
 M
an
us
cr
ip
t
Chemistry - A European Journal
This article is protected by copyright. All rights reserved.
